About 400 Mg Bevacizumab Concentrate For Solution For Intravenous Infusion
Experience the latest advancement in targeted oncology with 400 mg Bevacizumab Concentrate For Solution For Intravenous Infusion, a rare and masterful formulation designed to champion optimum patient outcomes. Each single-use glass vial contains 16 mL (25 mg/mL) of bevacizumab-ensuring precision and reliability for healthcare professionals. The clear to slightly opalescent solution is administered exclusively via intravenous infusion after dilution with 0.9% Sodium Chloride Injection, never dextrose. Purchase with confidence-each vial is accompanied by a comprehensive package insert to guide masterful administration and safety compliance.
Advanced Applications & Key Features
400 Mg Bevacizumab Concentrate For Solution For Intravenous Infusion is expertly crafted for oncology, with indications including metastatic colorectal, non-small cell lung, glioblastoma, renal cell, cervical, and ovarian cancers. Its ready-to-dilute composition ensures optimum compatibility for intravenous infusion only, administered exclusively by qualified professionals. The product features a stable sterile concentrate, shelf life of 24 months, and clear to pale brownish-yellow appearance. Disposal procedures and contraindications underscore its safety-driven, masterful design.
Market Value, Distribution & Samples
This premium oncology solution is supplied throughout India's main domestic markets and is available via major FOB ports for global distribution. Distributors, exporters, suppliers, and traders are welcome to inquire about the asking price and estimated market value, ensuring reliable procurement. Sample availability allows clinical evaluation prior to major purchase decisions, supporting thorough assessment and fostering trust in this optimum therapeutic solution.
FAQ's of 400 Mg Bevacizumab Concentrate For Solution For Intravenous Infusion:
Q: How should 400 Mg Bevacizumab Concentrate be administered?
A: The concentrate must be diluted using 0.9% Sodium Chloride Injection, USP, and administered only as an intravenous infusion by healthcare professionals. It should never be given as an intravenous push or bolus.
Q: What cancers is this product indicated for?
A: Bevacizumab is indicated for various cancers, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer.
Q: When should a dose of Bevacizumab not be given?
A: This product is contraindicated in individuals with hypersensitivity to bevacizumab or any component of the formulation. It must be used under strict medical supervision due to potential hypersensitivity reactions.
Q: Where can samples or market value information be obtained?
A: Samples and information on the asking price, estimate, and market value are available through distributors, suppliers, or exporters in India. Contact the main domestic market representatives or FOB port providers for details.
Q: What are the storage and disposal instructions?
A: Store Bevacizumab vials at 2C to 8C, do not freeze, and protect them from light. Any unused product or waste material should be disposed of in accordance with local regulations.